Karuna Therapeutics Inc

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Karuna Therapeutics reports positive trial results and strong financial outlook

Karuna Therapeutics is making significant progress in its key programs, with positive trial results and a focus on expanding its pipeline. Despite challenges in trial timelines and increased expenses, the company's strong financial position and strategic priorities position it well for future growth.

Karuna Therapeutics reports robust Q2 performance and eyes new indications

Karuna Therapeutics reported strong financials, progress on NDA submission, and ongoing Phase III programs.
The company's focus on cognitive benefits, broader efficacy, and potential new indications showcases strategic growth initiatives.
Challenges include competitive dynamics in Alzheimer's trials and uncertainties in the applicability of KarXT in certain patient populations.
Opportunities lie in exploring new indications, demonstrating cognitive benefits, and enhancing efficacy in mood and anxiety disorders.

Karuna Therapeutics excels in Q3, eyes global expansion for KarXT

Karuna Therapeutics demonstrated strong performance in Q3 with a focus on KarXT Phase III programs and NDA submission, supported by a healthy financial position.
Strategic strengths lie in maximizing KarXT value, positive payer interactions, and broad-based commercial strategies, while challenges include managing expenses and operational considerations.
Opportunities for growth include expanding the TRPC4/5 program, leveraging favorable mental health trends, and pursuing international market partnerships for KarXT.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Karuna Therapeutics is a biopharmaceutical company that develops treatments for psychiatric and neurological conditions. Karuna Therapeutics creates drugs that can significantly improve the lives of people who suffer from neurological and psychiatric illnesses, with a particular focus on schizophrenia and the behavioral symptoms of Alzheimer's disease. The company is skilled in neuroscience and has creative ideas for finding and developing new drugs. Karuna Therapeutics is advancing a pipeline of innovative drugs since its inception with the aim of significantly improving the lives of people suffering from these difficult conditions.

Investors apparently weren't thrilled by the company's licensing agreement with Zai Lab.

Why Karuna Therapeutics Stock Tumbled This Week

Zai Lab Ltd.

BOSTON & SHANGHAI & SAN FRANCISCO--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced their entry into an exclusive license agreement for the development, manufacturing, and commercia

Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the third quarter of 2021 and provided a general business update. “We continue to progress our late-stage clinical programs evaluating KarXT in schizophrenia, including the ongoing enrollment in our EMERGENT program, comprised of fou

Karuna Therapeutics Reports Third Quarter 2021 Financial Results and Provides General Business Update

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will participate in a fireside chat at the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021, at 8:40 a.m. ET. A live webcast of the fireside chat will be available on the Investor Relations page of Karun

Karuna Therapeutics to Present at 2021 Virtual Wells Fargo Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul, M.D., chief executive officer, president and chairman, will participate in a panel titled “Emerging Therapies for Psychiatric Disorders” at the Citi 16th Annual BioPharma Virtual Conference on September 8, 2021, at 10:40 a.m. ET. A live w

Karuna Therapeutics to Present at the Citi 16th Annual BioPharma Virtual Conference

Agree Realty

Allegiant Travel Company

Axsome Therapeutics

Coursera

Chart Industries

Health Catalyst Inc

LivePerson

PDC Energy Inc

Q2 Hld

Varonis Systems

A recent pullback has created buying opportunities for many small-cap stocks. Here are the ones the pros are most bullish on.

11 Small-Cap Stocks the Analysts Love for the Rest of 2021

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the second quarter of 2021 and provided a general business update. “The second quarter was an exciting one for Karuna as we've made important progress in advancing our mid- and late-stage clinical trials studying our lead asset, KarX

Karuna Therapeutics Reports Second Quarter 2021 Financial Results and Provides General Business Update

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul, M.D., chief executive officer, president and chairman will participate in a panel titled “The Brains of the Operation - Novel Approaches in Neuro” at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021 at 12:00 p.m.

Karuna Therapeutics to Present at 2021 Wedbush PacGrow Healthcare Virtual Conference

Combination therapy with patent protection through 2039. Sufficiently funded for cash run through 2023.

Karuna Therapeutics: Clear Path To NDA

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced data from its completed Phase 1b trial evaluating the safety and tolerability of KarXT (xanomeline-trospium) in healthy elderly volunteers. The Company had previously announced a preliminary analysis of data from the first two cohorts in the trial earlier

Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers

Annovis Bio

Arvinas Inc

Anavex Life Sciences

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Biohaven Pharmaceutical Hld

Biogen

Loncar Cancer Immunotherapy ETF

Denali Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

abrdn Life Sciences Investors 

iShares Nasdaq Biotechnology ETF

Defiance Nasdaq Junior Biotechnology ETF

INmune Bio Inc

Intra-Cellular Therapies

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Eli Lilly

Invesco Dynamic Biotechnology & Genome ETF

Prothena

Cassava Sciences Inc

Supernus Pharmaceuticals

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

Avadel Pharma

Neurocrine Biosciences

SAGE Therapeutics

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.

Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the first quarter of 2021 and provided a general business update. “This year is off to a very productive start, with the advancement of our early- and late-stage clinical programs, most notably the initiation and ongoing enrollment o

Karuna Therapeutics Reports First Quarter 2021 Financial Results and Provides General Business Update

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity, Karuna Therapeutics, Inc. (NASDAQ: KRTX) announced the pricing of an underwritten public offering.

PureTech Founded Entity Karuna Therapeutics Announces Pricing of Public Offering of Common Stock

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and year ended 2020 and provided a general business update. “This past year was foundational for Karuna. We realized significant milestones and achievements including the initiation of the first Phase 3 trial in ou

Karuna Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides General Business Update

PureTech Health PLC

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological condit

PureTech Founded Entity Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia

BOSTON--(BUSINESS WIRE)---- $KRTX #NEJM--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that results from the EMERGENT-1 Phase 2 clinical trial evaluating KarXT for the treatment of schizophrenia were published in the New England Journal of Medicine (NEJM). “The publication of the EMERGENT-1 Phase 2 trial results in the peer-reviewed New Eng

Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 9:20 a.m. EST. A live webcast of the presentation will be available on the Investor Relations page of K

Karuna Therapeutics to Participate at 10th Annual SVB Leerink Global Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Ronald Marcus, M.D., to Senior Vice President of Medical. In this role, Dr. Marcus will provide strategic and operational leadership of Karuna's clinical stage pipeline of novel neuropsychiatric medicines, including KarXT. “We are please

Karuna Therapeutics Announces Appointment of Ronald Marcus, M.D., as Senior Vice President of Medical

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Andrew Miller, Ph.D., chief operating officer and founder, will participate in a fireside chat at the ICR Conference 2021 on Thursday, January 14, 2021 at 3:15 p.m. EST. A live webcast of the presentation will be available on the Investor Relations pa

Karuna Therapeutics to Participate in the ICR Conference 2021

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul, M.D., chief executive officer, president and chairman, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 10:50 a.m. EST. A live webcast of the presentation will be available on the Investor

Karuna Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced the appointment of Denice Torres, J.D., to its Board of Directors effective December 22, 2020. “Denice is a highly respected leader with an exceptional ability to visualize and achieve operational success

Karuna Therapeutics Appoints Denice Torres, J.D., to its Board of Directors

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced the appointment of David Wheadon, M.D., to its Board of Directors. In addition, the Company announced that Ed Harrigan, M.D., will step down from the Board of Directors effective December 3, 2020. Dr. Har

Karuna Therapeutics Appoints David Wheadon, M.D., to Its Board of Directors

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced that senior management will participate in a fireside chat at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 2:40 p.m. EST. A live webcast of the fireside chat will be avai

Karuna Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced financial results for the third quarter of 2020 and provided a general business update. “The end of this year will be transformative for Karuna as we initiate our Phase 3 EMERGENT program and transition t

Karuna Therapeutics Reports Third Quarter 2020 Financial Results and Provides General Business Update

News for Karuna Therapeutics Inc Stock (KRTX)